64x Bio
PrivateLast Round
Series A
Jan 19, 2022
Est. Valuation
$2.14M
Total Funding Raised
$59.62M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
64x Bio is a biotechnology company that develops a high-throughput mammalian cell line discovery platform to optimize cell line design for biomanufacturing and therapeutic applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
64x Bio Comparables
Compare 64x Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NewBiologix | 88% | |
| Asimov | 83% | |
| Virica Biotech | 73% |
64x Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 19, 2022 | ||||
| Seed | Nov 16, 2020 | ||||
| Accelerator | Aug 1, 2018 |
Key People
Founding team and executive leadership
64x Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Refactor Capital | Series A, Seed |
| Future Ventures | Series A |
| SV Angel | Series A |
| Alix Ventures | Series A |
| Lifeforce Capital | Series A |
| Northpond Ventures | Series A |
| First Round Capital | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 1719% MoM, reaching 3.1K.
- Jan 19, 2022
$55M round led by Lifeforce Capital.
Recent news
Latest coverage and updates
- launchesJun 29, 2026
64xBio launched LV Apex Suite on Jun 29th '26.
64x Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about 64x Bio's valuation, stock price, and market status.
Is 64x Bio a public or private company?
64x Bio is a private company.
What is the current stock price of 64x Bio?
64x Bio is a private company with no public stock price. No recent secondary market data is available.
How much is 64x Bio worth (valuation)?
64x Bio's valuation is estimated at $2.1M based on funding round data.
Can I buy 64x Bio stock?
64x Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was 64x Bio's last funding round?
64x Bio's most recent funding round was Series A on August 22, 2018.
Who are the main investors in 64x Bio?
Key investors in 64x Bio include Refactor Capital, Lifeforce Capital, First Round Capital, Y Combinator, Fifty Years.
Will 64x Bio IPO soon?
No public IPO plans have been announced for 64x Bio.
How can I track 64x Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor 64x Bio's secondary market activity and sign up for updates.